Why Are There So Few FDA-Approved Therapeutics for Wound Healing?

Area of Science:

• Regenerative Medicine
• Biotechnology
• Drug Development

Background:

• The FDA has not approved new therapeutics for wound healing in over 25 years, unlike the 250+ drugs approved for various human tumors.
• Becaplermin gel (Regranex, 0.01% human recombinant PDGF-BB) remains the only FDA-approved therapeutic for wound healing, highlighting a significant gap in treatment options.
• The disparity in therapeutic advancements between wound healing and oncology, despite similarities in pathological descriptions like 'wounds that do not heal,' is a critical concern.

Purpose of the Study:

• To critically evaluate the historical therapeutic development strategies for wound healing.
• To identify the theoretical limitations of single-molecule-based approaches in addressing complex wound pathologies.
• To propose a paradigm shift necessary for the future development of effective wound healing therapeutics.

Main Methods:

• Comparative analysis of drug approval trends between wound healing and oncology.
• Theoretical assessment of molecular repair capabilities versus complex tissue regeneration requirements.
• Literature review and critical evaluation of existing wound healing therapeutic strategies.

Main Results:

• A stark contrast exists in therapeutic innovation, with wound healing lagging significantly behind oncology drug development.
• Single-molecule therapies are theoretically insufficient for addressing the multi-level, multi-cellular, and multi-pathway damage inherent in wound healing.
• The prevailing strategy of targeting single molecules for wound repair is fundamentally flawed.

Conclusions:

• The current single-molecule-based strategy for developing wound healing therapeutics is inadequate and requires a fundamental re-evaluation.
• Future advancements in wound healing necessitate a paradigm shift towards more comprehensive, multi-faceted therapeutic approaches.
• Addressing the deficit in wound healing therapeutics requires innovative strategies that move beyond the limitations of current molecular targets.